Information Provided By: 
Fly News Breaks for July 13, 2017
NVS, JUNO, KITE
Jul 13, 2017 | 05:55 EDT
Citi analyst Robyn Karnauskas believes the FDA's unanimous vote in favor of Novartis' (NVS) CAR-T bodes well for Kite Pharma (KITE) and Juno Therapeutics (JUNO). Yesterday's panel meeting provides a preview of what Kite can expect ahead of its November 29 FDA action date, Karnauskas tells investors in a research note. She believes the expert commentary from the panel has "overarching implications" for Kite and Juno, both of which are developing CAR-T therapies for multiple indications.
News For KITE;JUNO;NVS From the Last 2 Days
